T2 Biosystems, Inc.: Business Overview, Financials & Competitive Analysis
T2 Biosystems, Inc. scores 3/10 on the AskCyborg Cyborg Score (Challenged). Early-stage diagnostics company with promising technology but severe revenue contraction and negative equity require urgent turnaround or restructuring. In 2023, T2 Biosystems' revenue declined 67.75% to $7.19 million from $22.31 million, with net losses of $50.08 million. The company has negative shareholder equity of -$11.7 million and total debt.
What is T2 Biosystems, Inc.'s industry? T2 Biosystems, Inc. (t2biosystems.com) operates in In-Vitro Diagnostics. AskCyborg classifies T2 Biosystems, Inc. under In-Vitro Diagnostics in its company registry.
T2 Biosystems is an in vitro diagnostics company that develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, ...
Cyborg Score thesis
Early-stage diagnostics company with promising technology but severe revenue contraction and negative equity require urgent...
Read the full analyst-debate transcript →Get the Latest T2 Biosystems, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeT2 Biosystems, Inc. Overview
Pro stress-test →T2 Biosystems is an in vitro diagnostics company that develops and sells diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.
Strategic Profile
Pro stress-test →The company's products include the T2Dx Instrument, T2Candida Panel, and T2Bacteria Panel powered by proprietary T2 Magnetic Resonance (T2MR) technology, with an active pipeline that includes products for detection of additional sepsis pathogens and tests for Lyme disease. The company is positioned in the rapid diagnostics market, addressing critical care needs in sepsis and fungal infection detection.
Competitive Landscape
Pro stress-test →T2 Biosystems competes in the rapid molecular diagnostics space against established players like bioMérieux (BACT ALERT), Abbott Diagnostics (PANBIO), and Cepheid (GeneXpert), as well as emerging competitors in sepsis and fungal infection diagnostics. The company's direct-from-blood capability differentiates it from traditional culture-based methods, but commercial traction lags larger diagnostics firms.
Industry Context
T2 Biosystems, Inc. operates in In-Vitro Diagnostics.
Key facts
Founded: 2006 · Headquarters: Lexington, Massachusetts, US · Employees: N/A · Revenue: $7.19M (2023) · Market cap: N/A